These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

Jul 5, 2017
Sixty-seven per cent of patients with functional natural killer (NK) cells remained disease-free at a pre-determined end point that followed two years of treatment
Jun 29, 2017
Jun 20, 2017
Immune's subsidiary, CYTOVIA, to implement development and commercialization plan for Ceplene
Jun 19, 2017
Jun 15, 2017
Immune's subsidiary, Cytovia, plans commercialization activities in Europe and Latin America
 

print email rss